Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Non Operating Income (2016 - 2025)

Historic Non Operating Income for Voyager Therapeutics (VYGR) over the last 11 years, with Q3 2025 value amounting to $2.8 million.

  • Voyager Therapeutics' Non Operating Income fell 4172.42% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.1 million, marking a year-over-year decrease of 2010.39%. This contributed to the annual value of $19.0 million for FY2024, which is 6163.43% up from last year.
  • Per Voyager Therapeutics' latest filing, its Non Operating Income stood at $2.8 million for Q3 2025, which was down 4172.42% from $3.3 million recorded in Q2 2025.
  • Over the past 5 years, Voyager Therapeutics' Non Operating Income peaked at $4.9 million during Q2 2024, and registered a low of -$1.6 million during Q2 2021.
  • Moreover, its 5-year median value for Non Operating Income was $3.2 million (2022), whereas its average is $2.5 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first plummeted by 62766.67% in 2021, then surged by 591290.32% in 2023.
  • Quarter analysis of 5 years shows Voyager Therapeutics' Non Operating Income stood at $397000.0 in 2021, then skyrocketed by 140.05% to $953000.0 in 2022, then soared by 230.95% to $3.2 million in 2023, then skyrocketed by 39.38% to $4.4 million in 2024, then tumbled by 36.65% to $2.8 million in 2025.
  • Its Non Operating Income stands at $2.8 million for Q3 2025, versus $3.3 million for Q2 2025 and $3.7 million for Q1 2025.